Clinical & Translational Immunology

2022; e1400. doi: 10.1002/cti2.1400
www.wileyonlinelibrary.com/journal/cti

REVIEW

Modelling the tumor immune microenvironment for precision immunotherapy

Nathan J Mackenzie1,2, Clarissa Nicholls1,2, Abby R Templeton1,2,3, Mahasha PJ Perera1,2,3,4,5, Penny L Jeffery1,2,3,4, Kate Zimmermann1,6,7, Arutha Kulasinghe8, Tony J Kenna1,3,6,7, Ian Vela1,2,3,4,5, Elizabeth D Williams1,2,3,4 & Patrick B Thomas1,2,3,4

1School of Biomedical Sciences at Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, Australia
2Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia
3Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia
4Australian Prostate Cancer Research Centre – Queensland (APCRC-Q), Brisbane, QLD, Australia
5Department of Urology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
6Centre for Immunology and Infection Control, School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane, QLD, Australia
7Centre for Microbiome Research, School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane, QLD, Australia
8University of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD, Australia

Correspondence
PB Thomas or E Williams, School of Biomedical Sciences, Queensland University of Technology, Translational Research Institute (TRI), 37 Kent Street, Woolloongabba, Brisbane, QLD 4102, Australia.
E-mails: pb.thomas@qut.edu.au or ed.williams@qut.edu.au

Received 23 January 2022;
Revised 14 April 2022;
Accepted 7 June 2022
doi: 10.1002/cti2.1400

Clinical & Translational Immunology
2022; 11: e1400

Abstract
The complexity of the cellular and acellular players within the tumor microenvironment (TME) allows for significant variation in TME constitution and role in anticancer treatment response. Spatial alterations in populations of tumor cells and adjacent non-malignant cells, including endothelial cells, fibroblasts and tissue-infiltrating immune cells, often have a major role in determining disease progression and treatment response in cancer. Many current standard systemic antineoplastic treatments target the cancer cells and could be further refined to directly target commonly dysregulated cell populations of the TME. Recent developments in immuno-oncology and bioengineering have created an attractive potential to model these complexities at the level of the individual patient. These developments, along with the increasing momentum in precision medicine research and application, have catalysed exciting new discoveries in understanding drug–TME interactions, target identification, and improved efficacy of therapies. While rapid progress has been made, there are still many challenges to overcome in the development of accurate in vitro, in vivo and ex vivo models incorporating the cellular interactions that take place in the TME. In this review, we describe how advances in immuno-oncology and patient-derived models, such as patient-derived organoids and explant cultures, have enhanced the landscape of personalised immunotherapy prediction and treatment of solid organ malignancies. We describe and compare different immunological targets and perspectives on two-dimensional and three-dimensional modelling approaches that may

© 2022 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
be used to better rationalise immunotherapy use, ultimately providing a knowledge base for the integration of the autologous TME into these predictive models.

Keywords: co-culture, immuno-oncology, immunotherapy, patient-derived explants, patient-derived organoids, precision medicine

INTRODUCTION

For decades, surgical procedures coupled with non-targeted conventional therapies such as systemic chemotherapy and/or radiotherapy have represented standard of care (SOC) for the treatment of solid organ malignancies. However, these options lack tumor-specific drug targets, can be costly and do not always represent the most efficacious course of treatment for an individual patient.1 To combat these challenges, precision medicine aims to provide ‘the right treatment for the right person at the right time in their clinical management’ by incorporating information garnered from genetic profiling to aid in the identification of optimal therapy for the individual. Despite this, there is a still an urgent need to develop additional companion diagnostic tools that can predict drug response while considering the tumor heterogeneity specific to each patient. In the last decade, improvements in personalised patient-specific tumor models have allowed for a deeper understanding of the intricate relationship between the host immunity and the tumor microenvironment (TME), thus giving rise to an era of precision approaches to guide cancer therapy.2

With the approval of ipilimumab for treating metastatic melanoma in 2011,3 incorporation of immunotherapy regimens for the treatment of various cancers has become a viable therapeutic option in addition to conventional chemotherapies. When considering second-line regimens in solid tumors, which progress following SOC chemotherapy, immunotherapies provide alternative mechanisms to target cancer and, in some instances, provide durable long-term responses.4 Immune checkpoints are essential interactions that regulate immune responses and can be of a stimulatory or suppressive nature.5,6 In a normal homeostatic capacity, these axes have a major protective role in preventing immunodeficiency and autoimmunity.7 However, many solid tumors express immune-suppressive ligands, which are upregulated within the tumor and immune cells of TME, allowing tumor cells to evade host immune defences.8 Thus, the blockade of these checkpoints with monoclonal antibodies (mAbs) can restore or prolong the antitumor immune response.8 A small number of these mAbs have been developed for clinical use as immune checkpoint inhibitors (ICIs). However, despite durable clinical responses for subsets of melanoma, lung and bladder cancer patients, regimens of approved ICIs remain largely ineffective and difficult to predict as a monotherapy.9–11 Additionally, high levels of permanent and irreversible immune-related toxicity occur in a large subset of patients.12 Clinical biomarkers and/or bench-to-bedside in vitro prediction tools to direct the use of many ICIs are currently lacking. Barriers in the implementation and evaluation of companion diagnostic biomarker tests that are used to stratify patients for ICIs (i.e. tumor cell expression of PD-L1 and tumor mutation burden assessment) suggest that much remains to be discovered to fully understand ICI response. The development of rapid patient-directed models incorporating intra- and inter-patient tumor heterogeneity would allow ICI in a more targeted and rational manner, thus ameliorating the above issues and leading to more favorable and durable responses.13

Optimisation of personalised ICI therapy for solid tumors may be performed by utilising ex vivo platforms that most accurately replicate the biophysical, chemical, and cellular TME to model drug response at a patient-specific level.14 Inclusive of this is the co-culture of autologous components such as serum,15 and non-neoplastic host cells (including immune cells16 and other stromal components such as endothelium and fibroblasts) to achieve a more representative model. Patient-derived organoids (PDOs), resected tissue explants, bioprinting and organ-on-a-chip models represent potential 3D platforms, which more faithfully recapitulate the TME than current 2D methods do.14 Such developments have shown promise but are still in their infancy. Besides estimating checkpoint biomarker expression, clinicians lack standardised assays that can be used to inform treatment decisions. Thus, paramount
to the success of these models is the understanding of key functional immune components in tumorigenesis. Herein, we discuss whether the concept of a 3D immuno-oncological model inclusive of autologous stromal and/or immune interactions is a feasible and practical approach to predict immunotherapy response to guide precision treatment strategies in the context of the current understanding of the composition and modelling of the immune TME.

**IMMUNE CELLS OF THE TUMOR MICROENVIRONMENT**

The TME is manifested by cellular and acellular tumor–host interactions and has a role in governing growth, metastasis, host evasion and drug response. The TME is composed chiefly of the stroma, angiogenic factors and the inhibitory and stimulatory signals produced by infiltrating immune cells involved in innate and adaptive immunity (summarised in Figure 1). Additional cellular components include the tumor-associated fibroblasts, adipocytes and angiogenesis-promoting endothelial cells. Other contributing TME factors include a range of interstitial fluid pressures, shifting hypoxia gradients, metabolic factors, nutrient starvation, immunosuppressive cytokines, upregulated immune checkpoints and mechanical stresses. During tumorigenesis, the TME is disrupted such that the cell–cell and cell–stroma interactions are altered to activate new signalling pathways, neovascularisation and dysregulated cell death resistance mechanisms. Immunological changes affect not only tumor-infiltrating lymphocytes (TILs) but also circulating immune cells such as peripheral blood mononuclear cells (PBMCs). Broadly, there are two main categories of tumor-associated immune cells: tumor-suppressing or tumor-promoting cells.

**Tumor-suppressing cells**

During tumor cell elimination, effector T cells, including CD4+ helper (T_h) and CD8+ cytotoxic lymphocytes (CTLs), secrete cytokines IFN-γ and TNF-α to induce tumor cell death and recruit other effector cells. In addition, activated T_h cells produce the T-cell growth factor IL-2. Natural killer (NK) cells are recruited to tumor cells via identification of downregulated or altered MHC class I molecules. Additionally, CTLs and NK cells also secrete IFN-γ and TNF-α, which further potentiate apoptotic effects through the release of granzymes and perforin. IFN-γ and TNF-α, alongside stimulatory factors such as IL-6 and GM-CSF, promote an inflammatory response in the TME. CTLs, T_h and NK cells, along with phagocytic M1 ‘classically activated’ tumor-associated macrophages (TAMs) and N1-polarised neutrophils, and pro-inflammatory dendritic cells (DCs) make up the majority of tumor-suppressing immune cells present in the TME.

**Tumor-promoting cells**

In a state of favorable vascularisation, stromal composition and chemotactic signalling, the TME can recruit or induce cells into a state of tumor promotion. Regulatory T cells (Tregs) represent an immunosuppressive subset of T_h cells. Identified by detectable levels of membrane-bound CD25 and transcription factor forkhead box P3 (FOXP3), Tregs have an important immunosuppressive role in mediating immune self-tolerance and resolving inflammation. Tregs perform this role chiefly by the production of inhibitory molecules, and sequestering of IL-2- and cytotoxic T-lymphocyte antigen 4 (CTLA-4)-mediated suppression of antigen-presenting cells (APCs). However, within the TME this immunosuppressive action becomes problematic, acting principally on effector T cells and thereby disabling their antitumorigenic effects. Additionally, by inducing oxidative stress via the depletion of amino acids, suppressing recruitment of effector cells and promoting recruitment of regulatory cells, myeloid-derived suppressor cells (MDSCs) infiltrating in the TME can disrupt the efficiency of host antitumor immunity and increase metastatic potential. MDSCs also promote tumorigenesis through the induction of angiogenesis through secretion of proangiogenic factors such as vascular endothelial growth factor, matrix metalloproteinase 9 and prokinectin-2. Studies in both murine and human cell models have also shown that increased circulating levels of cancer-associated MDSCs reduce ICI therapy efficacy, most likely because of the general suppression of T-cell function and recognition. M2 (or ‘alternatively activated’) macrophages are a class of macrophage that unlike the M1 subset contribute to tissue repair and fibrosis via induction of immune suppression and an anti-inflammatory response.
IMMUNE CHECKPOINTS OF THE TUMOR MICROENVIRONMENT

Immune checkpoint inhibitors (ICIs) are arguably the most significant development in cancer therapy over the past decade and function as key inhibitory signalling molecules to attenuate the robust antitumor immune responses in the TME.32 ICIs are expressed on a wide range of cells and act throughout the early phase of immune activation and throughout the ongoing response to impair T-cell activation.33 The most widely investigated ICIs currently in immuno-oncology are PD-1 (CD279), PD-L1 (CD274, B7-H1) and CTLA-4 (CD152). Immune checkpoints are widely expressed on the surface of APCs, tumor cells and TILs and function as immunosuppressive receptors to induce CTL exhaustion and anergy.34 Others, including T-cell immunoglobulin and mucin domain 3 (TIM-3), lymphocyte activation gene 3 (LAG-3), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), V-domain Ig suppressor of T-cell activation (VISTA), and co-stimulatory molecules such as the TNF receptor/TNF superfamily members OX40 (CD134) and OX40 ligand (OX40L; CD252), are emerging clinical drug targets in several clinical settings (Figure 2). Approximately two thirds of all oncology trials are dedicated to T-cell-targeting immunomodulators (Table 1), and there are more than 3000 ongoing clinical trials (https://clinicaltrials.gov). CTLA-4 and PD-1/PD-L1 in particular have been found to be highly expressed in a wide range of malignancies and have subsequently attracted the most interest to date.35 Currently, there are a handful of FDA-approved ICIs targeting the CTLA-4 and PD-1/PD-L1 axes in various cancers, with several novel mAbs currently being explored for clinical efficacy.
While ICIs provide long-lasting efficacy for a subset of patients, a large majority do not respond to treatment and experience adverse side effects. An urgent clinical need necessitates the development of novel predictive biomarkers and personalised ICI testing in patient-derived tumor cells. Below, we review current and novel immune targets that are emerging in clinical and preclinical research.

**CTLA-4**

CTLA-4 is a B7/CD28 family membrane glycoprotein constitutively expressed on T cells and is a potent negative regulator of the antitumor T-cell response. Following TCR activation, CD80 (B7-1) or CD86 (B7-2) on APCs, resulting in T-cell maturation and subsequent immune function. CTLA-4, being structurally homologous to CD28, competes for CD80 at a higher affinity when trafficked to the cell membrane from cytoplasmic microvesicles, impairing IL-2 production and preventing T-cell maturation and causing immune suppression.

Treg cells constitutively express CTLA-4, which acts to promote immunosuppression in the TME. The first-in-class monoclonal anti-CTLA-4 antibody ipilimumab (Yervoy; Bristol Myers Squibb) was the first ICI to gain FDA approval and has been shown to induce durable responses, allowing a subset (16–20%) of advanced stage IV melanoma patients to achieve stable disease.

**PD-1/PD-L1**

Shortly after the discovery of CTLA-4, Honjo et al. identified a 288 amino acid type I transmembrane apoptosis-mediating protein, which they characterised as programmed death-1. The binding of PD-1 on T, B and NK cells to its ligand, PD-L1/PD-L2, found most commonly on DCs, epithelial cells and macrophages, lowers the threshold for apoptosis and ultimately results in T-cell depletion through T-cell receptor (TCR)-mediated PI3K/Akt/Ras–MEK/ERK signalling pathways. PD-L1 is detectable on the surface of many tumor types, including and not limited to: colorectal, bladder, breast, melanoma and lung cancers. Upregulation of this axis has been implicated in many malignancies and is perhaps the most well-studied immune checkpoint.

Owing to increased interest in the field, several immune checkpoints have been uncovered through revisiting the PD-1/PD-L1 axis in relation to other regulatory pathways. To date, approximately seven PD-1/PD-L1-targeting drugs are approved for over nine cancers (Figure 2), with many other inhibitors currently under development and or in clinical trials (> 1500 at
| Target       | Inhibitor (commercial name) | Trial name | Company                   | ClinicalTrials.gov Identifier | Trial phase | Trial stage | Malignancy                  | Clinical setting                                                                 |
|--------------|----------------------------|------------|---------------------------|-------------------------------|------------|------------|-----------------------------|---------------------------------------------------------------------------------|
| CTLA-4       | Ipilimumab (Yervoy)         | COSINR     | Bristol Myers Squibb     | NCT03232155                  | I          | Active, recruiting       | Stage IV NSCLC                  | nivolumab/ipilimumab plus either sequential or concurrent SBRT chemotherapy and immunotherapy-naive progressive mCRC |
|              |                            | /          |                          | NCT01688492                  | II         | Active, not recruiting  | MCRPC                        | Chemotherapy- and immunotherapy-naive progressive mCRC                            |
|              |                            | CheckMate 401 |                          | NCT02599402                  | III        | Complete               | Stage III melanoma            | Adjunct with nivo for treatment-naive melanoma                                   |
| Tremelimumab |                            | /          | Medimmune (AstraZeneca)  | NCT01843374                  | IIb        | Active, not recruiting  | Mesothelioma                  | Unresectable mesothelioma following first-line platinum-based regimen           |
|              | Tremelimumab               | /          |                          | NCT0357918                   | II         | Active, recruiting      | mUC                          | Post-anti-PD-1/PD-L1 therapy with no improvement following first-line SOC chemotherapy |
| LAG-3        | Relatilimab (BMS-986016)   | RELATIVITY | Bristol Myers Squibb     | NCT03470922                  | III        | Active, not recruiting  | Advanced melanoma             | Pretreatment, adjunct with nivo pretreatment with nivo                            |
|              |                            |            |                          | NCT04867615                  | II         | Active, recruiting      | HCC                          | Adjunct with nivo; post-TKI treatment IO therapy naive                           |
|              | Nivolumab (Opdivo)         |            | CheckMate649             | NCT02872116                  | III        | Active, not recruiting  | Gastric/GI, EAC                | > 50% PD-L1 expression, no EGFR, ALK, ROS1 mutations in combination with SOC chemotherapy|
|              | Pembrolizumab (Keytruda)   | KEYNOTE-630 | Merck                    | NCT03831167                  | III        | Active, recruiting      | cSCC                         | Post-surgery, post-radiation Post-surgery, post-radiation                        |
|              | Pembrolizumab              | KEYNOTE-672/ | Merck                    | NCT03361865                  | III        | Complete               | mUC                          | cis. ineligible, adjunct with epacadostat vs placebo                            |
|              |                            | ECHO-307   |                          |                              |            |                        |                              |                                                                                 |
|              | PD-1                       | PD-1       | EMPOWER -Lung 1          | Regeneron Pharmaceuticals    | III        | Active, not recruiting  | NSCLC                        | > 50% PD-L1 expression, no EGFR, ALK, ROS1 mutations in combination with SOC chemotherapy |
|              | Nivolumab (Opdivo)         |            | CheckMate649             | Bristol Myers Squibb         | III        | Active, not recruiting  | Gastric/GI, EAC                | > 50% PD-L1 expression, no EGFR, ALK, ROS1 mutations in combination with SOC chemotherapy |
|              | Pembrolizumab (Keytruda)   | KEYNOTE-630 | Merck                    | NCT03831167                  | III        | Active, recruiting      | cSCC                         | Post-surgery, post-radiation Post-surgery, post-radiation                        |
|              | Pembrolizumab              | KEYNOTE-672/ | Merck                    | NCT03361865                  | III        | Complete               | mUC                          | cis. ineligible, adjunct with epacadostat vs placebo                            |
|              |                            | ECHO-307   |                          |                              |            |                        |                              |                                                                                 |
|              | PD-L1                      | PD-L1      | BIRCH                    | Hoffmann-La Roche            | III        | Complete               | Stage III, Stage IV, or recurrent Stage IV NSCLC                               | PD-L1 pos tumors Maintenance following first-line platinum-based SOC Treatment naive with platinum-etoposide/tremelimumab Following SOC chemotherapy, unresectable cancer |
|              | Atezolizumab (Tecentriq)   | OAK        | POPULAR                  |                          | III        | Complete               | Stage IV NSCLC                  | PD-L1 pos tumors Maintenance following first-line platinum-based SOC Treatment naive with platinum-etoposide/tremelimumab Following SOC chemotherapy, unresectable cancer |
|              | Avelumab (Bavencio)        | JAVELIN Bladder 100 | Pfizer                  | NCT02603432                  | III        | Active, not recruiting  | SCLC                          | Maintenance following first-line platinum-based SOC Treatment naive with platinum-etoposide/tremelimumab Following SOC chemotherapy, unresectable cancer |
|              | Durvalumab (Imfinzi)       | CASPAN     | AstraZeneca              | NCT0343872                   | III        | Active, not recruiting  | SCLC                          | Maintenance following first-line platinum-based SOC Treatment naive with platinum-etoposide/tremelimumab Following SOC chemotherapy, unresectable cancer |
|              | PACIFIC                    |            |                          | NCT02125461                  | III        | Active, not recruiting  | NSCLC                         | Maintenance following first-line platinum-based SOC Treatment naive with platinum-etoposide/tremelimumab Following SOC chemotherapy, unresectable cancer |

(Continued)
| Target | Inhibitor (commercial name) | Trial name | Company         | ClinicalTrials.gov Identifier | Trial phase | Trial stage | Malignancy | Clinical setting                  |
|--------|----------------------------|------------|------------------|-------------------------------|-------------|-------------|------------|-----------------------------------|
| TIGIT  | Tiragolumab                | SKYSCRAPER-02 | Genentech        | NCT04256421                   | III         | Active, not recruiting | SCLC       | Combination atezo + CE           |
|        | Vbostolimab (MK-7684-001)   | /          | Merck            | NCT02964013                   | I           | Recruiting               | Advanced solid tumors | In combination with pembro |
|        | Efgilimab (OMP-313 M32)     | /          | Merco BioPharma  | NCT04761198                   | III         | Recruiting               | Advanced solid tumors | Undergoing evaluation with nivo |
|        | Sabatolimab (MBG453)       | /          | Novartis         | NCT02608268                   | III         | Active, not recruiting | Advanced solid tumors | Progression despite SOC, immunotherapy naïve |
|        | Cobolimab (T5R-022)        | AMBER      | GlaxoSmithKline (ex-Tesaro) | NCT02817633                   | I           | Recruiting               | Advanced solid tumors | First-in-human dose escalation and dose expansion |
|        | OX40L                      | SL-279252 (PD1-Fc-OX40L) | Shattuck Labs, Inc. | NCT03894618                   | I           | Recruiting               | Advanced solid tumors | First-in-human dose escalation and dose expansion |
|        | mRNA-2416                  | /          | ModernaTX, Inc.  | NCT03323398                   | III         | Active, not recruiting | Relapsed/refractory solid tumor malignancies or lymphoma | In combination with durvalumab |
|        | OX40                       | MEDI0562   | /                | NCT02705482                   | I           | Complete                 | Advanced solid tumors | First-in-human dose escalation and dose expansion in combination with durvalumab and tremelimumab |
|        | MEDI0562                   | /          | Medimmune (AstraZeneca) | NCT03336606                   | Ib          | Active, not recruiting | Advanced HNSCC or stage Ib/IIC melanoma | Single agent in the preoperative setting |
|        | MEDI6469                   | /          | Medimmune (AstraZeneca) | NCT02274155                   | Ib          | Active, not recruiting | HNSCC       | Stage III and IV HNSCC. Safety and feasibility of preoperative administration |

ALK, anaplastic lymphoma kinase; atezo, atezolizumab; CE, carboplatin and etoposide; Cis, cisplatin; CPS, combined positive score (PD-L1⁺ cells (tumor cells, lymphocytes, macrophages)/total number of viable tumor cells) x 100; cSCC, cutaneous squamous cell carcinoma; EAC, oesophageal adenocarcinoma; EGFR, epidermal growth factor receptor; GEJ, oesophagogastric junction; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; IO, immuno-oncology; mCRCP, metastatic castration-resistant prostate cancer; mUC, metastatic urothelial carcinoma; nivo, nivolumab; NSCLC, non-small-cell lung cancer; PDAC, pancreatic adenocarcinoma; PD-L1, programmed death-ligand 1; pembro, pembrolizumab; ROS1, ROS proto-oncogene tyrosine-protein kinase; SBRT, stereotactic body radiotherapy; SCLC, small-cell lung cancer; SOC, standard of care; and TKI, tyrosine kinase inhibitor.
current standing; https://clinicaltrials.gov). Both anti-PD-L1 agents, durvalumab (Imfinzi; Medimmune/AstraZeneca), avelumab (Bavencio; Merck & Pfizer) and atezolizumab (Tecentriq; Genentech), and anti-PD-1-targeting agents, nivolumab (Opdivo; Bristol Myers Squibb) and pembrolizumab (Keytruda; Merck Sharp & Dohme Corp), have shown durable responses and paved the way for treatment of many unresectable, mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) tumors, or cancers that have progressed following first-line platinum-based chemotherapy or chemoradiation regimens (in the case of non-small-cell lung carcinoma (NSCLC) with PD-L1 expression ≥ 1%).

TIM-3

TIM-3 is widely expressed and can be detected on CTLs, Tregs, B-cells NK cells, DCs, TAMs and tumor cells and promotes T-cell exhaustion through antagonism of TCR signalling and expansion of MDSCs within the immunosuppressed TME. The TIM-3/Gal-9 axis is the most widely studied and is known to induce apoptosis through Ca²⁺ influx. Thus, the blockade of this pathway can result in restored immune functionality in the TME. TIM-3 is distinctly perturbed among the CD8⁺ PD1⁺ T and Treg cells within the tumor TME, and the blockade in a preclinical setting has been found to be effective in models of pancreatic cancer, colorectal cancer and NSCLC. It has been previously demonstrated that resistance to anti-PD-1/PD-L1 treatment correlated with an adaptive upregulation of alternative immune checkpoints, including TIM-3. Consequently, promoting results have been seen with anti-TIM-3 mAbs used in combination with anti-PD-1/PD-L1 mAbs and oncolytic viral therapy in lung cancer. Approximately 15 companies are developing TIM-3-targeting antibodies, with Novartis (sabatolimab) the only one expecting Phase III trial outcomes in early 2027 in the clinical setting of high-risk myelodysplastic syndrome and chronic myelomonocytic leukaemia-2 (STIMULUS-MDS2; NCT04266301).

LAG-3

LAG-3 (CD223) is structurally homologous to CD4 and is expressed on peripheral Tregs, CTLs, B cells, NK cells and DCs. LAG-3 is also highly expressed on CD8⁺ TILs, and it has been proposed that LAG-3 may be used as an indicator of tumor prognosis and as a target for ICI therapy. While the exact mechanism of LAG-3 is to be fully elucidated, studies show that this molecule interacts with major histocompatibility complex (MHC) class II on APCs at a higher affinity than CD4 (~40 times higher) and suppresses T-cell activation and cytokine production, maturation and expansion. Conversely, it is also expressed by plasmacytoid DCs, which in turn express many of the immune checkpoints that exhausted T cells interact with. Notably, dual blockage of LAG-3 (using relatlimab) and PD-1 (using nivolumab) was shown to have effective synergism and higher clinical efficacy in a subset of melanoma patients with progressive disease who previously showed no durable response to anti-PD-1/PD-L1 monotherapy. However, further randomised, double-blinded Phase I/II trials are required to assess whether combining LAG-3 blockade with other ICIs leads to increased incidence and severity of irAEs.

TIGIT

TIGIT is a next-generation emerging target in immune checkpoint therapy. Expressed predominantly on activated CTLs, Tregs and NK cells, TIGIT binds to either poliovirus PVR or its homologue nectin-2 expressed on APCs and tumor cells to attenuate T-cell-mediated pattern recognition and NK-mediated cytotoxicity. Expression of TIGIT has since been observed in NSCLC, urothelial, melanoma, gastric, colorectal, breast and prostate cancers. Not unlike TIM-3, TIGIT has also been found in many cases to be adaptively upregulated in patients treated with anti-PD-1/PD-L1 and is potent enough to abrogate CD8⁺ T-cell and NK cell cytotoxicity. In vivo, this occurs through the suppression of CD8⁺ T-cell cytotoxicity via IL-10 production. TIGIT⁺ Tregs, when compared to Tregs lacking expression, suppress the function of Th1 inflammatory cell types through distorting CD4⁺ T-cell response towards a Th2 profile. Favorable results have been achieved in a preclinical setting using a cotherapy of anti-PD-1/PD-L1 and anti-TIGIT. The anti-TIGIT mAb tiragolumab is currently in Phase III clinical trials in combination with atezolizumab and carboplatin/etoposide in chemotherapy-naïve small-cell lung cancer (SKYSCRAPER-02; NCT04256421) (Table 1). Alongside these trials, randomised investigation into tiragolumab and
atezolizumab combinations in the clinical setting of early-stage NSCLC (SKYSCRAPER-03; NCT04513925), advanced oesophageal cancer (SKYSCRAPER-07; NCT04543617) and metastatic oesophageal cancer (SKYSCRAPER-08; NCT04540211) is currently recruiting.

VISTA

Currently, VISTA represents one of the more recent immune checkpoints implicated in infiltrated–inflamed TMEs. Preliminary studies indicate VISTA negatively mediates immune cell quiescence, achieved principally by interaction with V-set and immunoglobulin domain-containing 3 (VSIG-3). In the excessively acidic environment caused by lactic acid production within the TME, VISTA selectively binds with PSGL-1 to suppress T-cell activity. Recent reports show that VISTA is predominantly expressed on myeloid lineage cells, Tregs and naive T\(_{\text{c}}\) cells – where its potential as an immunotherapy target is becoming increasingly appreciated. Additionally, VISTA is also expressed, albeit to a lesser extent, on monocytes, neutrophils and NK cells. VISTA has been documented to be highly overexpressed in some genitourinary cancers and high-grade serous ovarian cancer, when compared to normal tissue. Mulati et al. discovered that by generating VISTA-knockdown variants of human ovarian and endometrial cancer cell lines (COV504 and HEC1A, respectively), T-cell proliferation and cytokine secretion were markedly restored. The development of pH-selective VISTA antibodies in immune checkpoint-based cancer therapy is currently still unknown; however, anti-VISTA mAbs (e.g. the novel SNS-101 anti-VISTA mAb; Sensei Biotherapeutics, Inc.) may potentiate anti-PD-1/PD-L1-induced antitumor immunity. Given its important role in regulating innate and adaptive immune responses, VISTA is a promising target for immunotherapeutic intervention.

IMMUNE-ACTIVATING CHECKPOINTS

OX40/OX40L axis

The OX40/OX40L co-stimulatory axis represents the next generation of immunotherapies, which are aimed at reshaping the antitumor immune TME. OX40L is expressed on many APCs such as DCs, macrophages and activated B cells but is also expressed on tumor cells, endothelial cells and smooth muscle cells. Its binding to OX40 serves as a co-stimulatory signal to induce cytokine production, T-cell survival, clonal division and development of memory T cells. OX40/OX40L signalling has been shown to abolish Treg immunosuppressive functions, reduce Foxp3 expression and promote the proliferation of CD4\(^+\) and CD8\(^-\) T lymphocytes. Like CTLA-4, OX40 is upregulated in TILs when compared to its very low basal expression in peripheral blood lymphocytes. The literature regarding the expression of OX40/OX40L in tumors is still relatively unclear. Kashima et al. determined that high serum levels of OX40 and OX40L in NSCLC were associated with poor prognosis, although high levels of OX40L were associated with improved survival following treatments with ICIs. In the TME, secreted OX40L from cancer-associated fibroblasts (CAFs) under stress conditions can facilitate cisplatin resistance and inhibition of apoptosis of lung adenocarcinoma cells through activation of NF-\(\kappa\)B/BCL-XL pathways. However, other reports indicate that in different contexts, high OX40 expression is associated with increased CD4\(^+\) TIL infiltration and a favorable immune profile. In oral squamous cell carcinoma (OSCC) and hepatocellular carcinoma, high OX40 is associated with advanced disease, possibly reflecting the immune-exhausted, immunosuppressive TME. Similarly, Lecerf et al. showed that approximately 85% of head and neck squamous cell carcinoma (HNSCC) tumors showed high expression levels of OX40/OX40L, where OX40L mRNA expression in the context of low PD-1 expression was associated with high recurrence rates. Both OX40 and OX40L are overexpressed in muscle invasive bladder tumors, where the risk of recurrence in non-muscle invasive bladder cancer is reported to be approximately twofold higher with OX40L mRNA overexpression. Clinically, humanised monoclonal agonists targeting the OX40/OX40L axis have shown promise by decreasing intratumoral OX40\(^+\) FOXP3\(^+\) cells to enhance adaptive immunity in the solid tumor TME. Combining conventional immune checkpoint inhibition of CTLA-4 and PD-1 may enhance the Treg depletion within the tumor and further potentiate the CD4\(^+\) and CD8\(^-\) antitumor immunity (Table 1).
In vitro/ex vivo replication and preservation of the TME

The success of a prescribed immunotherapy relies on an understanding of the complex network of immune evasion mechanisms intrinsic to the TME. Although ICIs are increasingly central to regimens prescribed in advanced recurrent solid tumors, our understanding of the rational use of the various therapeutic options to provide the best clinical outcome is still lacking. Additionally, only a small subset of patients has a meaningful clinical response to ICIs and some tumor types remain completely refractory or develop treatment resistance. This leads to one of the greatest challenges in the field of precision immunotherapy, which is the development of immune-intact, robust, reproducible and cost-effective immunotherapy testing platforms to model treatment responses. Such a platform should be one that incorporates cells homologous to the host TME, models the immunosuppressive features of the TME and retains cellular viability over drug treatment duration. Advances in biotechnology have made patient material more accessible through patient-derived organoid (PDO) generation and tumor tissue in explant cultures. Despite well-established and novel immunotherapies being approved and employed in the treatment of various solid tumors, in vitro and ex vivo models may be able to replicate patients' immune TME, predict personalised responses to ICIs and provide predictive information on the safety of immunotherapies (current models are shown in Figure 3 and summarised in Table 2). In the last few years, there has been progress in developing microphysiological in vitro systems to tease apart preclinical immune responses. Here, we summarise the major models used to investigate ICI responses, including their advantages and disadvantages and incorporation of TME elements.

CO-CULTURE MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE

Cell line models of cancer

Immortalised cell lines derived from human cancers remain one of the most standard and well-established preclinical tools for the evaluation of cancer cell activity and drug efficacy.75 Cell lines are relatively low cost, common and easily manipulated to yield large supplies of experimental material, can be used to identify novel drugs and are easily imaged using standard microscopy techniques.76 2D cultures are

![Figure 3](https://biorender.com)
| Submerged organoid/spheroid co-cultures | 3D microfluidic cultures | Primary tissue cultures |
|---------------------------------------|--------------------------|------------------------|
| Tissue processing                     |                          |                        |
| Physical and enzymatic dissociation of tissue followed by filtration for 100-μm fragments and generation of organoids in ULA plates | Standard preparation of PDOs, which are then embedded into ECM-based biomaterial | Tissue is sliced at a thickness of 100–400 μm or physically minced into small fragments |
| Culture Preparation                   |                          |                        |
| Free-floating organoids in an ALI or suspended in a suspension medium (e.g. containing Matrigel™ or Happy Cell®) | PDOs in collagen are injected into a 3D microfluidic culture device | Tumor slices or fragments directly cultured with anticancer drugs in a free-floating or suspended setting |
| Autologous PBMCs, native TILs and anticancer drugs embedded into suspension | Primary tumor bioinks are laid onto surface of microfluidic chamber | Tumor slices embedded onto a vehicle such as a scaffold, gel or sponge |
| Advantages                            |                          |                        |
| Relatively easy expansion and enrichment of PDOs; displays phenotypic changes of the source tumor | Requires only a small number of cells, media and reagents per test | Accounts for tumor heterogeneity across the tissue |
| Can be used to assess drug efficacy    | Enables the study of tumor–immune interactions; faithful recapitulation of the TME | Preserves diverse population of immune cells, fibroblasts and stroma in TME |
| Autologous components such as PBMCs are easily co-cultured | Immune cells can be added to assess infiltration kinetics | Allows immune TME of primary tissues to be reconstituted |
| Representation of tumor–TME interactions | Can be highly reproducible and imaged in real time |                        |
| Limitations                           |                          |                        |
| Native stromal and immune components may not be present | Small-scale application only | Difficulty in precisely regulating fragment and slice size |
| Short cultivation periods             | Process requires specialised equipment | Viability of primary tissue is highly variable |
| No standard protocols                 | Currently limited standardisation for 3D bioprinters | Lack of uniformity in the composition of slices |
| If Matrigel™ is used: Lot-to-lot variation and mouse origin can make it sometimes unsuitable for human studies | Long-term culturing has not been reported | Immune cell and fibroblast count declines over 1–2 months |
| No standard protocols                 | No standard protocols | No standard protocols |
| Potential in studying the tumor–immune axis |                     |                        |
| Co-culture of autologous PDOs and PBMCs enriches tumor-reactive T cells, which can be used to assess the efficiency of T-cell-mediated cytotoxicity | Recapitulates response to ICIs | Functional T-cell activation and responses to ICI antibodies are faithfully preserved |
| Enables assessment of tumor organoid killing by co-culture with TILs | Useful culture system to test therapeutic combinations to enhance response | Conservation of TCR expression in tissue slices and fragments for accurate immune–tumor interaction |
|                                | Useful in evaluation of drug toxicity and interaction | Cytokine profiling through conditioned media is also possible |

ALI, air–liquid interface; ECM, extracellular matrix; ICI, immune checkpoint inhibitor; PBMC, peripheral blood mononuclear cell; PDO, patient-derived organoid; TCR, T-cell receptor; TIL, tumor-infiltrating lymphocyte; TME, tumor microenvironment; and ULA, ultra-low attachment.
subject to relatively uniform medium perfusion, and thus are exposed to supraphysiological levels of growth factors, nutrients and oxygen, which need to be physically replaced every few days. As such, few 2D models are employed to tease apart preclinical response to immune-targeting agents. Employing a simple 2D immune cell co-culture to model immunosuppression, Zheng et al. demonstrated that co-culture of breast cancer cell lines with anti-CD3/CD28-stimulated healthy donor PBMCs significantly decreased T-cell activity as indicated by reduced INF-γ and IL-2 secretion in cells with high PD-L1 levels. Flexible label-free biosensor systems such as the xCELLigence system have been used to provide real-time quantitative assays to monitor effector cell:target cell interactions. Cerignoli et al. developed a real-time potency assay employing sensitive impedance measurements to directly investigate PC-3 prostate cancer cell cytotoxicity changes when co-cultured with healthy donor PBMCs. Demonstrating the utility of this model to quantitatively assess immunotherapeutic approaches, anti-PD-1 treatment in combination with prestimulated PBMCs showed increased PC-3 cytotoxicity. However, because of a poor recapitulation of the TME and cellular drug response, the aforementioned approaches hold limited potential as a tool to provide efficient patient-derived in vitro model screening. While primary cells can be developed from the patient’s tumor, the field is moving away from this method of culture as this application requires extensive lineage testing, considerable time and materials. Given their reproducibility and ease of establishment, 2D co-cultures hold most utility during the research and development phases of immunotherapeutic approaches.

**Patient-derived organoids**

The increasingly widespread adoption of three-dimensional (3D) cell line models (spheroids) has been considered an important improvement from conventional 2D cultures. Subsequently, PDO technology has gained popularity as an effective and rapid 3D tool that better retains the tumor-specific genetic and molecular diversity of the original host. They differ from established cell line spheroids by the retention of multiple organ-specific cellular populations and stem cell components to form more complex and personalised milieu that more closely simulates the solid tumor mass. Compared to 2D and 3D cell line-based spheroids, PDOs better reproduce many tumor features, including hypoxia, nutrient diffusion, metabolism (i.e. decreased glucose uptake) and the eventual formation of an immunosuppressive central necrotic core. Additionally, PDOs offer more efficient cell–cell and cell–matrix interactions, influencing cell phenotype, signalling pathways, adhesion and overall mechanosensing. PDOs are compatible with high-throughput assays that in turn rapidly provide quantifiable and clinically relevant data. Additionally, PDOs can be established from a small sample of tissue such as that obtained in a fine-needle biopsy, allowing potential generation from small cancers, or those in which sampling is limited.

Patient-derived organoids that can retain host-derived immune cell subsets and organoid-based propagation en bloc with immune stroma are a valuable candidate for holistic approaches to 3D immuno-oncology TME modelling. However, these models historically are prohibited by host-derived immune cells rapidly losing viability before studies can explore patient responses. Pancreatic ductal adenocarcinoma PDOs cultured with autologous PBMCs and CAFs have been found to retain certain elements of stromal influence in the TME. Replicative of the native TME, activation of myofibroblast-like CAFs and tumor-influenced T-cell infiltration was able to be observed in this model. PDOs inclusive of autologous CD3 and CD56 TILs derived from lung adenocarcinoma, clear cell renal cell carcinoma and melanoma were able to be retained in a collagen gel matrix-embedded air-liquid interface (ALI) cultures. Neal et al. demonstrated that PDOs derived from surgical resections (shown to retain both epithelial cell myofibroblasts and syngeneic TILs) could be isolated with the original T-cell receptor spectrum preserved in vitro. Interestingly, myofibroblast populations decreased following passage in PDOs generated from kidney and colon tumors, a feature not noted in PDOs derived from NSCLC. Immunofluorescence and fluorescence-activated cell sorting analysis showed that NSCLC, clear cell renal carcinoma and melanoma retained CD8+, CD4+ (Th) T cells, CD14+ or CD69+ macrophages, NK, NKT and B cells. Addition of IL-2 was effective at preserving the endogenous TIL subsets, which had total life of approximately 1 month in organotypic media. Critically, anti-PD-1 monotherapy (nivolumab) was able to...
effectively activate the PD-1-expressing CD3+ T-cell compartment and induce significant cytotoxicity in PDO cultures. In a feasibility study, Votanopoulous et al. described the ‘immune enhanced patient organoid’ model, a patient-specific symbiotic co-culture model pairing patient-matched lymph node specimens or PBMCs with patient-derived melanoma PDOs. Their hydrogel-based system showed that embedding autologous tumor and lymph node cells together generated personalised immune-competent PDOs that recapitulated clinical responses to ICIs targeting PD-1 and CTLA-4 in 6 of 7 patients. In our experience, lymph nodes are not commonly available in surgical specimens and represent a major limitation to the adoption of models such as these.

Co-culturing with autologous peripheral blood cells enables the investigation of response of endogenous TILs. Dijkstra et al. demonstrated that by culturing PDOs with PBMCs, it is possible to induce the expansion of tumor-reactive T cells. PDOs generated from mismatch repair-deficient NSCLC and colorectal cancer cultured with autologous PBMCs resulted in a significant increase in CD8 expression in T-cell populations. When combined with PD-1 blockade, an increase in PDO-induced IFN-γ secretion was observed, indicating the usefulness of this platform for the examination of T-cell-mediated killing of cancer cells. As PDOs can be sustained for multiple weeks, it is evident from studies investigating PDOs derived from NSCLC and melanoma that each routine passaging varies the levels of stromal myofibroblasts, PDO TILs and expression of smooth muscle actin and vimentin further from the tumor original state. Whether this is common between all tumor types is something to expand upon. Furthermore, despite being more faithful models than cell lines, PDOs lack functional vasculature and it is likely that not all cell types of the TME are present in any particular organoid culture. Apart from CRC, standardisation or reproducibility of these models—including the composition of growth media and cytokine cocktails—has not been reached for most tumor types. The few studies to date have only incorporated pembrolizumab, nivolumab (anti-PD-1) and ipilimumab (CTLA-4) therapy, and other ICIs or combination therapies with SOC therapies have only been described for feasibility studies in melanoma. Applications of cancer immunology in these models are becoming more popular as optimised methods and tools are increasingly published.

**Patient-derived explants**

Organotypic tumor explants are useful preclinical models to rapidly assess the physiological properties of primary tissues in an ex vivo setting. Explants are most easily generated from tissue obtained from surgical procedures. Tissue is then processed into slices, usually in the range of 100–400 μm, via manual processing or fragmentation using a device such as a vibratome or tissue chopper. Tissue explants can be directly cultured in a defined medium (which may contain autologous serum) with autologous components such as PBMCs and are typically fixed in formalin prior to paraffin embedding for subsequent histopathological and immunohistochemical analyses. Currently, the use of tumor tissue explants for immunotherapy testing is lacking; however, their potential usefulness in predicting clinical outcomes is becoming increasingly recognised. Ex vivo metastatic colorectal cancer tissue slices taken from a small cohort of patients demonstrated clinically relevant sensitivity to SOC agents and pembrolizumab (as measured by treatment-induced cell death). Explants obtained from human primary breast cancer have also been evaluated for immunotherapy prediction. Transcriptomic analysis of breast cancer explants cultured with PD-1, PD-L1 and TIM-3 inhibitors showed an upregulation in expression of pathways pertaining to antitumor immune response. These data also revealed that the blockade of some immune checkpoints can induce upregulation of others as a compensatory measure (including of ICOS, CTLA4, BTLA and OX40L in response to anti-PD-L1 and anti-TIM3 treatment), suggesting that the explant culture technique may be used to test the sequential combination of immunotherapies and other SOC therapies. NSCLC tissue slices cultured with autologous PBMCs reveal a revitalised activation of innate immunity pathways. Overall, the utility of explants as a tool for precision immunotherapy is in its infancy but warrants deeper investigation. Preserving T-cell function for an extended period of time continues to be a challenge, with studies indicating a rapid drop in CD3+ cell viability after about 3–4 weeks. Tissue slices have not been used widely for immunophenotyping and immune checkpoint discovery beyond murine models and...
thus represent an opportunity to incorporate clinical tumor samples in this functional testing platform.

**Emerging preclinical immunotherapy prediction models**

Microfluidics-based ‘organ-on-a-chip’ (also known as microphysiological systems) are favored next-generation platforms for modelling drug response in an *in vitro* environment. Such systems may be precisely manipulated to better recapitulate the spatial location of the cells, vascular regions and biophysical forces in the TME (Figure 3). Additionally, important factors for immuno-oncological investigations such as chemokine and oxygen rates can be precisely controlled. These chips are most commonly composed of polydimethylsiloxane (PDMS) and glass and contain many microchannels and compartments that can be subject to minute and accurate fluidic and biochemical adjustments. The control over these parameters, alongside design choices in channel architecture and cellular contents, allows for many organs and niches of the human body to be recapitulated to a potentially high degree of accuracy. The transparent substrates used also have an ideal optical index that is advantageous for standard microscopy imaging. In an immuno-oncology setting, organs-on-a-chip have been used to model anti-PD-1/PD-L1 therapy in a small number of malignancies. Cytokine profiling of metastatic melanoma patient-derived xenografts (PDXs) and PDOs combined with autologous myeloid and lymphoid populations in a short-term 3D microfluidic culture has demonstrated the enhancement of response to anti-PD-1 when co-treated with anti-TBK1/IKKε inhibitors. Furthermore, Cui et al. described a patient-derived ‘glioblastoma-on-a-chip’ model to assess inhibition of PD-L1 and CSF-1R across various molecular subtypes of glioblastoma (GBM). It was discovered through this platform that in comparison with proneural GBM, glioblastomas affecting the mesenchymal niche attracted significantly higher levels of CD163⁺ M2 TAMs and PD-1/PD-L1 and responded better to ICI treatment. The organ-on-a-chip model is yet to...
| Model type | Co-culture | Malignancy | Immune cells (E:T) | Technology | Prestimulation | ICIs used | Analysis method | Time frame | Comments | References |
|------------|------------|------------|-------------------|------------|---------------|-----------|----------------|------------|----------|------------|
| *Ex vivo*2D | NSCLC (LLC), CRC (CT26) | CD8⁺ T cells | Cell culture flask | Nil | αPD-L1 (in vivo) | Luciferase, CD107 degradation, flow cytometry | 2 days | *Autologous* | *Pimentel et al. 100* |
| 2D | Prostate (PC-3) and breast (MCF7) | PBMC, NK (NK92), T cell (TALL-104), B cell (Raji), CAR-T (various E:T) | xCELLigence RTCA system | IL-2 | αPD-1 | Cellular impedance changes in cellular attachment strength, flow cytometry | 70 h | *Allogeneic* | *Cerrignoli et al. 78* |
| 2D | Breast, lung, liver | Jurkat, PBMC | Cell culture flask | αCD3, αCD28 | αPD-1, αPD-L1 | RT-qPCR, flow cytometry, immunoblot | 2 days | *Allogeneic* | *Zheng et al. 77* |
| Spheroid | CRC (HT-29), PDAC (PSN-1), GBM (U251MG), lung (H1299) | T cells, NK (10:1) | ULA plates | Nil | αPD-1, αPD-L1 | IHC, Luciferase (luminescence), flow cytometry | 4 days | *Allogeneic* | *Zboralski et al. 101* |
| Spheroid | CRC (L5174T, LoVo) | PBMC (10:1) | Hanging drop | IL-2, IgG-IL-2v | Nil | IHC, cytomeric bead array, flow cytometry | 4 days | *Allogeneic* | *Herter et al. 102* |
| Spheroid | CRC (HT-29, DLD1) | T cells, NK (10:1) | ULA plates | IL-15, IL-7 | Nil | Flow cytometry, bright-field and fluorescent microscopy (spheroid volume and caspase 3/7 staining) | 6–7 days | *Allogeneic* | *Courau et al. 103* |
| Spheroid | Breast (MDA-MB-231) | PBMC (1:1) | Scaffold free, liquid overlay | PMA/Ionomycin | Nil | Brightfield microscopy (spheroid area), CFSE and CellTracker© Orange CMTMR, flow cytometry, ELISA (IFN-ϒ) | 10 days | *Allogeneic* | *Saraiva et al. 104* |
| PDO | PDAC | CD3⁺ T cells (1:1) | Matrigel | αCD3, αCD28 | Nil | Flow cytometry, immunofluorescence microscopy (spheroid area), CFSE and CellTracker© Orange CMTMR, flow cytometry, ELISA (IFN-ϒ) | 6 days | *Autologous* | *Tsai et al. 95* |
| PDO | Melanoma | PBMC and lymph node cells (1:1) | HA/collagen-based hydrogel | Nil | αPD-1 (pembrolizumab) αCTLA-4 (ipilimumab) | LIVEDGEAD (Thermo Fisher), immunofluorescence, CellTiter-Glo 3D | 10 days | *Autologous* | *Votanopoulos et al. 97* |
| PDO | NSCLC, CRC | CD8⁺ T-cell (3:1) | Matrix scaffold (Geltrex) | FN-3, IL-2, anti-CD28 | αPD-1 | Live-cell imaging (CellTrace Far Red), flow cytometry | 14 days | *Autologous* | *Cattaneo et al. 105* |
| PDO | CRC, NSCLC | PBMC (20:1) | Matrix scaffold (Geltrex) | FN-3, IL-2, anti-CD28 | αPD-1 | Flow cytometry, fluorescent microscopy (CellTrace Yellow, Far Red, caspase-3/7 probe), IHC, Live imaging | 14 days | *Autologous* | *Dijkstra et al. 98* |
| PDO | ccRCC, NSCLC, melanoma, bladder | *In situ* TILs | All technique (collagen gel matrix embedded into membrane) | IL-2, αCD3, αCD28 | αPD-1 (nivolumab) | Flow cytometry, qRT-PCR, IHC | 7 days | *Autologous* | *Neal et al. 96* |
| PDO | Chordoma | *In situ* TILs (CD8⁺ T cells) | Tissue pieces | 2% Matrigel-coated microchambers | αPD-1 (nivolumab) | Fluorescence imaging (% DAPI-stained cells) | 24 h | *Autologous* | *Scognamiglio et al. 90* |

(Continued)
| Model type                          | Malignancy       | Immune cells (E:T) | Technology | Prestimulation | ICIs used                                      | Analysis method                        | Time frame | Comments  | References |
|------------------------------------|------------------|--------------------|-------------|----------------|------------------------------------------------|----------------------------------------|------------|-----------|------------|
| Tissue explant                     | Breast           | In situ TILs       | Cryopreserved –2- to 4-mm manually sliced explants in 6-well tissue culture plates | IL-2 | αPD-1 (pembrolizumab), αPD-L1 (atezolizumab), αTIM3 | Flow cytometry                        | 9 days     | Autologous | Saleh et al. 2019 |
| Organotypic slice culture          | PDAC             | Nil                | 250-μm-thick slice, PTFE membrane | Nil | αPD-1 (nivolumab) | Live microscopy, flow cytometry, cytokine quantification (Luminex assay) | 2-6 days   | Autologous | Seo et al. 2017 |
| 3D microfluidic culture            | HNSCC            | PBMC (NA)          | 3D PDMS microfluidic chip | Nil | αPD-L1, αIDO 1 | Fluorescent microscopy (CellTrace Far Red, VioRed for enumeration) | 3 days     | Allogeneic | Al-Samadi et al. 2018 |
| 3D microfluidic culture/2D microfluidic culture | HeLa cells | NK (NK-92) (NA) | Injection-moulded microfluidic device, cell culture flask | Nil | Nil | Fluorescent microscopy (CSFE, Far Red), live imaging | 24 h       | Allogeneic | Park et al. 2019 |
| 3D microfluidic culture            | HGSC, NSCLC      | In situ TILs       | COP microfluidic device design | Nil | αPD-1 (pembrolizumab), αCTLA-4 (pilliminumab) | Immunofluorescence, cytokine EUSA     | 5-9 days (ex vivo) | Autologous | Aref et al. 2019 |

2D, two-dimensional; 3D, three-dimensional; ALI, air–liquid interface; CAR-T, chimeric antigen receptor T cells; ccRCC, clear cell renal cell carcinoma; CD, cluster of differentiation; CMTMR, 5- (and 6)-(((4-chloromethyl)benzoyl)amino)tetramethylrhodamine; COP, cyclic olefin polymer; CRC, colorectal cancer; CSFE, carboxyfluorescein succinimidyl ester; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DAPI, 4',6-diamidino-2-phenylindole; EUSA, enzyme-linked immunosorbent assay; E:T, effector-to-target ratio; GBM, glioblastoma; HGSC, high-grade serous carcinoma; ICI, immune checkpoint inhibitor; IDO1, indoleamine 2,3-dioxygenase 1; IgG, immunoglobulin G; IHC, immunohistochemistry; IFN-γ, interferon-gamma; IL-2, interleukin-2; NA, not available in study; NK, natural killer; NSCLC, non-small-cell lung cancer; PBMC, peripheral blood mononuclear cell; PCa, prostate cancer; PD-1, programmed death-1; PDAC, pancreatic ductal adenocarcinoma; PD-L1, programmed death-ligand 1; PDMS, polydimethylsiloxane; PMA, phorbol 12-myristate 13-acetate; PTFE, polytetrafluoroethylene; RTCA, real-time cell analysis; RT-qPCR, reverse transcription–quantitative real-time polymerase chain reaction; TILs, tissue-infiltrating lymphocytes; TIM3, T-cell immunoglobulin mucin-3; ULA, ultra-low attachment.
fully realise its translational and clinical potential; however, initial promising results, combined with informed chip and assay optimisation, will undoubtedly lead to a greater impact in future.97

Towards the integration of immunotherapy co-culture precision medicine tools

By capturing individual patient diversity, 3D models that also retain TME elements provide platforms to explore patient drug responses in clinical settings where immunotherapy is an option. Such an assay would be used alongside current clinical, biomarker-supported therapies, and within a clinically relevant time frame. However, the translation of these model systems into clinical settings is complex. As discussed above, each personalised model has benefits that may provide important information as a companion diagnostic assay during a patient’s clinical management. Immune-retaining PDOs and novel bioengineered constructs could potentially serve as important tools to direct treatment choice at the bedside, following tumor recurrence and ancillary to clinical trials. Furthermore, in the setting of ineligibility for chemotherapy or unresectable tumors, it is paramount that patient-derived immune-encompassing models are developed towards clinical utility to help direct immunotherapy alongside ICI pathology screening (Figure 4). To instruct patient care, a number of significant hurdles will need to be addressed, including the standardisation and cost of patient-derived immune co-cultures (i.e. media formulations and use of biological and synthetic matrices), optimised clinical workflows to utilise surgical resections (i.e. ethics and clinical partnerships with industry), increasing the establishment rates (i.e. increasing PDO success rates) and refinements on the speed and quality of sample processing pipelines to culture-to-drug treatment workflows (Figure 4). Additionally, a lack of standardised quality control and drug treatment endpoint analysis methods currently prevent integration into the clinical space. As more studies incorporate TME components, producing larger-scale and higher-resolution data, improvements in automation and context-driven mathematical modelling of the tissue milieu will help address these key significant hurdles and will allow randomised controlled trials to evaluate the usefulness of 3D models as clinical tools. In the coming years, the development of novel technologies and refinement of the culture parameters for these models have the potential to impact immunotherapy rationalisation, and thus the approach to treating cancer and the way patient care is personalised (Table 3).

CONCLUDING REMARKS

The landscape of 3D tissue recapitulation is in a state of rapid innovation and optimisation and has provided translational immuno-oncology with novel platforms for therapeutic screening. In addition, the theory of culturing tumor-derived material with interfacing components of the TME niche has great potential to advance the personalisation of effective anticancer treatment. Short-term immuno-oncological co-cultures have been fruitful, but long-term modelling continues to be a challenging prospect. Issues surrounding viability of both the tumor model and immune cells (or other autologous cellular components) become increasingly prominent with time. It is important that efforts to increase viability of these components alter phenotypic properties of the recapitulated TME as little as possible. Cytokines such as IL-2, IL-6 and GM-CSF can be incorporated for the preservation and expansion of immune cells, and replenishing culture media will offer a degree of protection from non-specific cell death; however, these will require further validation of robustness in the long term. It is also evident that a greater majority of studies focus on T-cell-specific immune checkpoint interactions despite incorporating a wider population of immune cells. Further investigation is required on the therapeutic implication on the immune checkpoints of myeloid-derived cells and non-T-lymphoid cells (NKs) in co-culture. Beyond this, co-cultures could potentially be used to rapidly compare immunological responses between multiple metastatic sites in individual patients within a contained setting. Organ-on-a-chip models also have significant potential to model the cancer–immune axis beyond the TME and examine aspects such as the contribution of lymphatic and mesenchymal components. Continued optimisation of 3D immunological co-culture techniques will influence the landscape of translational precision immunotherapy, enabling new discoveries and providing opportunities to develop personalised, functional testing platforms that can predict treatment efficacy to improve patient outcomes.
ACKNOWLEDGMENTS

This research was supported by funding from a Princess Alexandra Research Foundation Award (EDW, IV, PBT) and the Medical Research Future Fund (MRFF) Rapid Applied Research Translation Program (Centre for Personalised Analysis of Cancers; EDW, IV, Grant ID GAS9729). The Translational Research Institute receives support from the Australian Government.

AUTHOR CONTRIBUTIONS

Nathan Mackenzie: Conceptualization; investigation; visualization; writing – original draft; writing – review and editing. Clarissa Nicholls: Writing – review and editing. Abby Templeton: Writing – review and editing. Mahasha Perera: Writing – review and editing. Penny Jeffery: Writing – review and editing. Kate Zimmermann: Writing – review and editing. Arutha Kulasinghe: Writing – review and editing. Tony Kenna: Conceptualization; writing – original draft; writing – review and editing. Ian Vela: Conceptualization; funding acquisition; project administration; resources; supervision; writing – review and editing. Patrick Thomas: Conceptualization; funding acquisition; project administration; resources; supervision; writing – original draft; writing – review and editing.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Smith GL, Lopez-Olivo MA, Advani PG et al. Financial burdens of cancer treatment: a systematic review of risk factors and outcomes. J Natl Compr Canc Netw 2019; 17: 1184–1192.
2. Ochoa de Olza M, Oliva M, Hierro C, Matos I, Martin-Liberal J, Garralda E. Early-drug development in the era of immuno-oncology: are we ready to face the challenges? Ann Oncol 2018; 29: 1727–1740.
3. Ledford H. Melanoma drug wins us approval. Nature 2011; 471: 561.
4. Pilard C, Ancion M, Delvenne P, Jerusalem G, Hubert P, Herfs M. Cancer immunotherapy: It’s time to better predict patients’ response. Br J Cancer 2021; 7: 927–938.
5. Efremova M, Rieder D, Klepsch V et al. Targeting immune checkpoints potentiates immunooediting and changes the dynamics of tumor evolution. Nat Commun 2018; 9: 32.
6. Sadeghi Rad H, Monkman J, Warkiani ME et al. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev 2021; 41: 1474–1498.
7. He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res 2020; 30: 660–669.
8. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293–12297.
9. Wong A, Gyorki DE. Second-line immunotherapy in patients with metastatic melanoma. Lancet Oncol 2021; 22: 746–748.
10. van Dijk N, Gil-Jimenez A, Silina K et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med 2020; 26: 1839–1844.
11. Schoenfeld JD, Giobbe-Hurder A, Ranasinghe S et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2022; 2: 279–291.
12. Naing A, Hajjar J, Gulley JL et al. Strategies for improving the management of immune-related adverse events. J Immunother Cancer 2020; 8: e001754.
13. Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity 2020; 52: 17–35.
14. Templeton AR, Jeffery PL, Thomas PB et al. Patient-derived explants as a precision medicine patient-proximal testing platform informing cancer management. Front Oncol 2021; 11: 787697.
15. Tang Y, Xu Q, Yan M et al. Autologous culture method improves retention of tumors' native properties. Sci Rep 2020; 10: 20455.
16. Sherman H, Gitschier HJ, Rossi AE. A novel three-dimensional immune oncology model for high-throughput testing of tumoricidal activity. Front Immunol 2018; 9: 857.
17. Jin MZ, Jin WL. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther 2020; 5: 166.
18. Winkler J, Abisoey-Oggunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun 2020; 11: 5120.
19. Brassart-Pasco S, Brézillon S, Brassart B, Ramont L, Oudart J-B, Monboisse JC. Tumor microenvironment: extracellular matrix alterations influence tumor progression. Front Oncol 2020; 10: 397.
20. Holl EK, Frazier VN, Landa K, Beasley GM, Hwang ES, Nair SK. Examining peripheral and tumor cellular immunome in patients with cancer. Front Immunol 2019; 10: 1767.
21. Ribeiro Franco PI, Rodrigues AP, de Menezes LB, Pacheco MM. Tumor microenvironment components: allies of cancer progression. Pathol Res Pract 2020; 216: 152729.
22. Zhang Y, Guan XY, Jiang P. Cytokine and chemokine signals of T-cell exclusion in tumors. Front Immunol 2020; 11: 594609.
23. Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther 2021; 28: 5–17.
24. Ben-Shmuel A, Biber G, Barda-Saad M. Unleashing natural killer cells in the tumor microenvironment-the next generation of immunotherapy? Front Immunol 2020; 11: 275.
25. Binnewies M, Roberts EW, Kersten K et al. Understanding the tumor immune microenvironment (time) for effective therapy. Nat Med 2018; 24: 541–550.

26. Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci 2019; 110: 2080–2089.

27. Jóźwicki W, Brożyna AA, Siekiera J, Slominski AT. Frequency of CD4+CD25+FOXP3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal. Oncotarget 2016; 7: 11450–11462.

28. Davidov V, Jensen G, Mai S, Chen SH, Pan PY. Analyzing one cell at a time: analysis of myeloid cell contributions in the tumor immune microenvironment. Front Immunol 2020; 11: 1842.

29. Kumar V, Patel S, Tcyganov E, Gabriovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 2016; 37: 208–220.

30. Vafaei S, Zekiy AO, Khanamir RA et al. Combination therapy with immune checkpoint inhibitors (ICls), a new frontier. Cancer Cell Int 2022; 22: 2.

31. Lu X, Horner JW, Paul E et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 2017; 543: 728–732.

32. Tang XY, Shi AP, Xiong YL et al. Clinical research on the mechanisms underlying immune checkpoints and tumor metastasis. Front Oncol 2021; 11: 693321.

33. Collier JL, Weiss SA, Pauken KE, Sen DR, Sharpe AH. Not-so-opposite ends of the spectrum: CD8+ T cells dysfunction across chronic infection, cancer and autoimmunity. Nat Immunol 2021; 22: 809–819.

34. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734–1736.

35. Buchbinder E, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016; 39: 98–106.

36. Johnson DB, Reynolds KL, Sullivan RJ et al. Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncol 2020; 21: e398–e404.

37. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1: 220–228.

38. Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003; 100: 4712–4717.

39. Hersh EM, O’Day SJ, Powderly J et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011; 29: 489–498.

40. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887–3895.

41. Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 2018; 18: 153–167.

42. O’Malley DP, Yang Y, Boisot S et al. Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases. Mod Pathol 2019; 32: 929–942.

43. Zhou X, Ding X, Li H et al. Upregulation of TIM1 and PD-1 in colorectal cancer with mismatch-repair deficiency. Immunol Invest 2021; 50: 338–355.

44. Eckstein M, Strissel P, Strick R et al. Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. J Immunother Cancer 2020; 8: e00162.

45. Mok TSK, Wu YL, Kudaba I et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (keynote-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019; 393: 1819–1830.

46. Pлимак ER, Bellmunt J, Gupta S et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 2017; 18: 212–220.

47. Tang F, Wang F, An L, Wang X. Upregulation of Tim-3 on CD4+ T cells is associated with Th1/Th2 imbalance in patients with allergic asthma. Int J Clin Exp Med 2015; 8: 3809–3816.

48. Sakuishi K, Ngjow SF, Sullivan JM et al. TIM3/FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Onco Targets Ther 2013; 2: e23849.

49. Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev 2017; 276: 97–111.

50. Koyama S, Akbay EA, Li YY et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 2016; 7: 10501.

51. Sun F, Guo ZS, Gregory AD, Shapiro SD, Xiao G, Qu Z. Dual but not single PD-1 or Tim-3 blockade enhances oncolytic virotherapy in refractory lung cancer. J Immunother Cancer 2020; 8: e00294.

52. Keane C, Law SC, Gould C et al. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Adv 2020; 4: 1367–1377.

53. Andrews LP, Marciscano AE, Drake CG, Vignali DAA. LAG3 (CD223) as a cancer immunity target. Immunol Rev 2017; 276: 80–96.

54. Lichtenegger FS, Rothe M, Schnorfel FM et al. Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. Front Immunol 2018; 9: 385.

55. Ascierto PA, Melero I, Bhatia S et al. Initial efficacy of anti-ligand activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (ME-L) previously treated with anti–PD-1/PD-L1 therapy. J Clin Oncol 2017; 35: 9520.

56. Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol 2012; 188: 3869–3875.
57. Papanicolaou-Sengos A, Yang Y, Pabla S et al. Identification of targets for prostate cancer immunotherapy. Prostate 2019; 79: 498–505.
58. Hung AL, Maxwell R, Theodros D et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in gbm. Onco Targets Ther 2018; 7: e1466769.
59. Bottino C, Castriconi R, Pende D et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003; 198: 557–567.
60. Yasinska IM, Sakhnevych SS, Pavlova L et al. Identification of urine markers for prediction of non-muscle invasive bladder cancer. J Urol 2019; 201: 1956–1967.
61. Yuan L, Tatineni J, Mahoney KM, Freeman GJ. VISTA: a mediator of quiescence and a promising target in cancer immunotherapy. Trends Immunol 2021; 42: 209–227.
62. Johnston RJ, Su LJ, Pinckney J et al. VISTA is an acidic pH-selective ligand for PSGL-1. Nature 2019; 574: 565–570.
63. Mulati K, Hamanishi J, Matsumura N et al. VISTA expressed in tumour cells regulates T cell function. Br J Cancer 2019; 120: 115–127.
64. Gao J, Ward JF, Pettaway CA et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 2017; 23: 551–555.
65. Zong L, Zhou Y, Zhang M, Chen J, Xiang Y. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer. Cancer Immunol Immunother 2020; 69: 33–42.
66. Jensen SM, Maston LD, Gough MJ et al. Signaling through OX40 enhances antitumor immunity. Semin Oncol 2010; 37: 524–532.
67. Kitamura N, Murata S, Ueki T et al. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity. Int J Cancer 2009; 125: 630–638.
68. Kashima J, Okuma Y, Hosomi Y, Hishima T. High serum levels of OX40 and OX40 ligand (OX40L) correlates with reduced survival in patients with advanced lung adenocarcinoma. Oncology 2020; 98: 303–310.
69. Li Y, Chen Y, Miao L et al. Stress-induced upregulation of TNSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells. Cancer Lett 2021; 497: 212–220.
70. Sani AI, Rubab ZE, Usman S, Ahmed SZ, Hosein M, Shahid MA. Serum levels of OX40 in early and late-stage oral squamous cell carcinoma. Cureus 2021; 13: e14597.
71. Xie K, Xu L, Wu H et al. OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis. Onco Targets Ther 2018; 7: e1404214.
72. Lecerf C, Kamal M, Vacher S et al. Immune gene expression in head and neck squamous cell carcinoma patients. Eur J Cancer 2019; 121: 210–223.
73. Le Goux C, Vacher S, Pignot G et al. mRNA expression levels of genes involved in antitumor immunity: identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer. Onco Targets Ther 2017; 6: e1358330.
74. Glisson BS, Leidner RS, Ferris RL et al. Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors. Clin Cancer Res 2020; 26: 5358–5367.
75. Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst 2013; 105: 452–458.
76. Kaur G, Dufour JM. Cell lines: valuable tools or useless artifacts. Spermatogenesis 2012; 2: 1–5.
77. Zheng Y, Fang YC, Li J. PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett 2019; 18: 5399–5407.
78. Cerignoli F, Abassi YA, Lamarche BJ et al. In vitro immunotherapy potency assays using real-time cell analysis. PLoS One 2018; 13: e0193498.
79. Mastri M, Ramakrishnan S, Shah SD et al. Patient derived models of bladder cancer enrich the signal of the tumor cell transcriptome facilitating the analysis of the tumor cell compartment. Am J Clin Exp Urol 2021; 9: 416–434.
80. Kim J, Koo BK, Knoblich JA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol 2020; 21: 571–584.
81. Yuki K, Cheng N, Nakano M, Kuo CJ. Organoid models of tumor immunology. Trends Immunol 2020; 41: 652–664.
82. Guenti S, Hoke ATK, Yu KP, London NR Jr. Organoid and spheroid tumor models: techniques and applications. Cancer 2021; 13: 874.
83. Liu L, Yu L, Li Z, Li W, Huang W. Patient-derived organoid (PDO) platforms to facilitate clinical decision making. J Transl Med 2021; 19: 40.
84. Higa A, Takahashi N, Hiyama G et al. High-throughput in vitro assay using patient-derived tumor organoids. J Vis Exp 2021; 14: 172.
85. Tsai S, McOlash L, Palen K et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer 2018; 18: 335.
86. Neal JT, Li X, Zhu J et al. Organoid modeling of the tumor immune microenvironment. Cell 2018; 175: 1972–1988.
87. Votanopoulos KI, Forsythe S, Sivakumar H et al. Model of patient-specific immune-enhanced organoids for immunotherapy screening: feasibility study. Ann Surg Oncol 2020; 27: 1956–1967.
88. Dijkstra KK, Cattaneo CM, Weeber F et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 2018; 174: 1586–1598.e1512.
89. Lukonin I, Serra D, Challet Meylan L et al. Phenotypic landscape of intestinal organoid regeneration. Nature 2020; 586: 275–280.
90. Davies EJ, Dong M, Gutekunst M et al. Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices. Sci Rep 2015; 5: 17187.
91. Nagaraj AS, Bao J, Hemmes A, Machado M, Närhi K, Verschuren EW. Establishment and analysis of tumor slice explants as a prerequisite for diagnostic testing. J Vis Exp 2018; 29: 141.
92. Martin SZ, Wagner DC, Hörner N et al. Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer. BMC Cancer 2019; 19: 1030.

93. Saleh R, Toor SM, Al-Ali D, Sasidharan Nair V, Elkord E. Blockade of PD-1, PD-L1, and TIM-3 altered distinct immune- and cancer-related signaling pathways in the transcriptome of human breast cancer explants. Genes 2020; 11: 703.

94. Fan TWM, Higashi RM, Song H et al. Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues. Elife 2021; 10.

95. Ma Q, Wang Y, Lo AS, Gomes EM, Junghans RP. Cell density plays a critical role in ex vivo expansion of T cells for adoptive immunotherapy. J Biomed Biotechnol 2010; 2010: 386545 1, 13.

96. Ma C, Peng Y, Li H, Chen W. Organ-on-a-chip: a new paradigm for drug development. Trends Pharmacol Sci 2021; 42: 119–133.

97. Sun W, Luo Z, Lee J et al. Organ-on-a-chip for cancer and immune organs modeling. Adv Healthc Mater 2019; 8: e1801363.

98. Ma Y-HV, Middleton K, You L, Sun Y. A review of microfluidic approaches for investigating cancer extravasation during metastasis. Microsystems Nanoeng 2018; 4: 17104.

99. Cui X, Ma C, Vasudevaraja V et al. Dissecting the immunosuppressive tumor microenvironments in glioblastoma-on-a-chip for optimized PD-1 immunotherapy. Elife 2020; 9: 9.

100. Olivo Pimentel V, Yaromina A, Marcus D, Dubois LI, Lambin P. A novel co-culture assay to assess anti-tumor CD8+ T cell cytototoxicity via luminescence and multicolor flow cytometry. J Immunol Methods 2020; 487: 112899.

101. Zboralski D, Hoehlig K, Eulberg D, Frömming A, Vater A. Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade. Cancer Immunol Res 2017; 5: 950–956.

102. Herter S, Morra L, Schlenker R et al. A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. Cancer Immunol Immunother 2017; 66: 129–140.

103. Courau T, Bonnereau J, Chicoteau J et al. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment. J Immunother Cancer 2019; 7: 74.

104. Saraiva DP, Matias AT, Braga S, Jacinto A, Cabral MG. Establishment of a 3D co-culture with MDA-MB-231 breast cancer cell line and patient-derived immune cells for application in the development of immunotherapies. Front Oncol 2020; 10: 1543.

105. Cattaneo CM, Dijkstra KK, Fanchi LF et al. Tumor organoid-T-cell coculture systems. Nat Protoc 2020; 15: 15–39.

106. Scognamiglio G, De Chiara A, Parafioriti A et al. Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors. Br J Cancer 2019; 121: 979–982.

107. Seo YD, Jiang X, Sullivan KM et al. Mobilization of CD8+ T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer. Clin Cancer Res 2019; 25: 3934–3945.

108. Al-Samadi A, Poor B, Tuomainen K et al. In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients. Exp Cell Res 2019; 383: 111508.

109. Park D, Son K, Hwang Y et al. High-throughput microfluidic 3D cytotoxicity assay for cancer immunotherapy (caci-impact platform). Front Immunol 2019; 10: 1133.

110. Aref AR, Campisi M, Ivanova E et al. 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab Chip 2018; 18: 3129–3143.
In this article, we discuss several clinically significant immune checkpoint markers and review the current *in vitro* and *ex vivo* immune co-culture platforms that have applications for translational precision immunotherapy in solid tumors. The figure was created with Biorender.com.